Nona Biosciences Announces Strategic Collaboration with GeneQuantum
SUZHOU, China, July 17, 2023 /PRNewswire/ -- On July 14, 2023, GeneQuantum, a leading pioneer committed to innovative bioconjugation technology, and InxMed, a clinical-stage biotechnology company dedicates on developing innovative therapies targeting drug resistance for hard-to-treat solid tumors, signed a collaboration agreement. GeneQuantum granted non-exclusive licensing of its proprietary conjugation technology to InxMed, supporting the development of the next generation of targeted conjugate ADC drugs.
After joining forces last year to work on an antibody-drug conjugate (ADC) to treat brain cancer, China’s GeneQuantum Healthcare and South Korea’s Aimed Bio are expanding their partnership to encompass up to five more therapies.
SUZHOU, China, July 6, 2023 /PRNewswire/ -- GeneQuantum Healthcare, a leader in the innovative bioconjugation technologies for ADC new drug development, announced the expansion of its partnership with a South Korean biotech company Aimed Bio today. This strategic collaboration aims to jointly develop up to five new ADC drugs to address unmet clinical needs.
GeneQuantum Healthcare (GQ), a global innovative biotechnology company dedicated to the development of the next generation bioconjugate drugs, and WuXi XDC, a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that they have entered into a strategic collaboration for conjugation technology licensing and ADC drug development.
GeneQuantum Healthcare (Suzhou) Co., Ltd., a company specializing in site-specific bioconjugation for next generation biotherapeutics, has signed an...
SUZHOU, China, Sept. 15, 2021 /PRNewswire/ -- GeneQuantum Healthcare, an industry-leading biotech company dedicated to the next generation bioconjugate drugs based on the innovative intelligent ligase-dependent conjugation (iLDC) technology platform, announced the appointment of Dr. Li Wan as the Senior Vice President and Head of Global Regulatory Affairs, Dr. Weimeng Zhao as Vice President of Quality Research and Quality, to further strengthen the GeneQuantum management team.
GeneQuantum Healthcare and BrighGene Biomedical (Suzhou) Co.,Ltd. signed a co-development agreement for antibody immune agonist conjugate (AIAC), GQ1007. GQ1007 is a new type of antibody-drug conjugate. It is an antibody conjugated to a potent immune agonist. In recent years, immunotherapeutic antibody drugs targeting PD-1 and PD-L1 (representing immune checkpoint inhibitors) have revolutionized cancer therapy. Even though the superior efficacy of immune checkpoint inhibitor treatment has shown great benefit, many cancer patients do not respond to such treatment.